New cancer drug combo enters first human tests
NCT ID NCT06205706
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 42 times
Summary
This early-phase trial is testing a new experimental drug called BI-1910, given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (including lung and liver cancers) that have not responded to standard treatments. The main goals are to see if the drug is safe, what dose is best, and how the body handles it. Only 35 participants are enrolled, and the study is not yet designed to prove the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
HM Sanchinarro
Madrid, Spain
-
Hospital Fundacion Jimenez Diaz
Madrid, Spain
-
Hospital HM Nou Delfos
Barcelona, 08023, Spain
-
Hospital universitario Virgen del Rocio
Seville, Spain
-
Karolinska University Hospital, Solna
Stockholm, Sweden
-
Lund University Hospital
Lund, Sweden
-
Rigshospitalet
Copenhagen, Denmark
-
Universitätsklinikum Essen
Essen, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI-1910 (an experimental antibody) and pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early, first-in-human trial with only 35 participants. It is designed mainly to check safety and dosing, not to prove the drug works. Many early-stage cancer drugs fail to show benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.